Bristol Myers Wins FDA Approval for Zenbexus, Debuting New Myeloma Drug Class
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Bristol Myers Squibb has received FDA approval for Zenbexus, a treatment for advanced multiple myeloma. This marks the debut of a new class of drugs known as CELMoDs, which are designed to target and degrade specific proteins involved in the disease.
The approval is a significant milestone for Bristol Myers, as Zenbexus is the first drug in this novel category to gain clearance from the FDA, expanding treatment options for patients with this challenging blood cancer.
Bristol Myers Squibb
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“<figure><div><img”
biopharma dive — Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene“The FDA approved a treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of drugs for the blood cancer.”
stat news — STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class